Hims & Hers Health, Inc. (HIMS) is turning heads on Wall Street. The stock closed its latest trading session at $58.68, a +1.79% jump from the previous day, outpacing the S&P 500's modest 0.02% gain. While the Dow dipped by 0.14%, the tech-heavy Nasdaq managed a 0.33% increase. But Hims' performance is really catching investors' eyes.
Over the past month, HIMS has climbed 16.68%, significantly exceeding the Medical sector's 1.92% and the S&P 500's 4.93% gains. This impressive growth has investors eagerly anticipating the company's upcoming earnings report, scheduled for August 4, 2025.
Earnings Expectations Sky High
Analysts project Hims & Hers Health, Inc. will report earnings of $0.18 per share, a staggering 200% year-over-year increase. Revenue estimates are equally optimistic, with a consensus projecting $551.84 million, a 74.83% surge compared to the same quarter last year. Looking ahead to the full year, Zacks Consensus Estimates anticipate earnings of $0.75 per share and revenue of $2.35 billion, representing significant shifts of +177.78% and +58.88%, respectively, from the previous year.
Analyst Confidence Growing
Keep an eye on any revisions to analyst estimates for Hims & Hers Health, Inc. Positive revisions often signal analysts' confidence in the company's near-term business trends and profit potential. Empirical research suggests a direct correlation between these revisions and future stock price performance.
Adding fuel to the fire, Hims stock is soaring amid a spike in bullish options activity. Despite a quiet news day, call option volumes have surged, exceeding the 20-day average. This trend mirrors previous rallies where increased call volumes coincided with significant price increases.
Short Squeeze Potential?
With a substantial short interest as a percentage of float, around 36% as of the end of June, a short squeeze could further drive the stock price upward as short sellers cover their positions during the option-induced rise.
Investors are also closely watching Hims' weight-loss business, particularly its sales of knockoff versions of Ozempic and Wegovy, which previously led to a public dispute with Novo Nordisk. The August 4th earnings report will provide crucial insights into the performance of this segment.